Organon Stock: The Overlooked Merck Spinoff, Undervalued!

Organon Stock: The overlooked Merck spinoff came to my radar as I looked at Warren Buffett’s Berkshire Hathaway’s portfolio recently.

However, since its debut in the stock exchange, its activity has been pretty muted to date.

To understand more about its business, you can read more from Organon's investor relations site:
https://www.organon.com/investor-rela...

Its key business in Established Brands had been facing decline in revenues over the past few years. And that’s a key reason for Organon’s depressed valuation currently.

However, we are seeing lights at the end of the tunnel from its other growing operating segments - Women’s Health and Biosimilars, which will drive the growth of the company moving forward.

Once there’s more certainty in Organon’s top and bottom lines trajectory, we can expect the market to value the company at higher multiples.

Brokerage accounts that I'm using. | Use my links below for free stocks and commission-free trading:
Tiger Brokers: https://www.tigerbrokers.com.sg/activ...

Don't miss out on the next business knowledge and investment sharing!

Subscribe and click on the Bell Notification:
   / @carepital  

Learn to build the investment portfolio that's right for you
@ https://www.carepital.com
Receive exclusive updates on investing, business and personal improvement tips!
Tools. Ideas. Strategies.

Start - 0:00
#1: Business overview - 0:20
#2: Why share price is depressed - 01:57
#3: Growth - 03:19
#4: Modest debt level - 05:19
#5: Valuation - 06:00
#6: Ending notes - 07:07

Follow us on Social Media for first hand updates:
Facebook:   / carepital  
LinkedIn:   / carepital  
Instagram:   / carepital